

GLAXOSMITHKLINE PLC  
Form 6-K  
July 17, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 17, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of an increase in interests in Ordinary shares purchased at a price of £12.13 per share, and Ordinary share ADRs purchased at a price of \$47.89 per ADR in GlaxoSmithKline plc on 14 July 2008, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 10 July 2008.

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A P Witty	210.24	
Mr J S Heslop	42.33	
Dr M M Slaoui	61.80	
Mrs C E Bruck Slaoui	19.16	
Mr C Viehbacher		121.51
Mr S M Bicknell	27.38	
Mr J M Clarke	130.72	
Mr M Dunoyer	79.18	
Mr E J Gray	79.46	
Mr D Learmouth	47.64	
Mr W C Louv		39.04
Mr D J Phelan		119.17
Dr D Pulman		68.94
Mr D S Redfern	0.35	
Ms C Thomas	59.79	
Mr J R Stéphenne	221.56	
Mr S M Werner		39.72

The Company and the above named persons were advised of this information on 16 July 2008.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Deputy Company Secretary

17 July 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 17, 2008

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc